Zurletrectinib

佐来曲替尼

Report date: 2025/12/16 09:28:40
NME

Base Information

Drug NameZurletrectinib
Drug Alias Name卓乐替尼宜诺欣ICP-723
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTropomyosin-related kinase inhibitors
TargetsTropomyosin-related kinase
Therapy Area/IndicationsSolid tumoursCentral Nervous System Neoplasms
Global Approved IndicationsSolid tumours
Approved Indications in ChinaSolid tumours
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/09
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Innocare Pharma Tech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnoCare Pharma IncBeijing Innocare Pharma Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A